KBR Secures Two-Year Renewal of EPCM Contract with Basra Oil Company for the Majnoon Oil Field in Iraq
Under the contract, KBR will continue to provide comprehensive EPCM services to help BOC sustain forecasted production capacity, enhance operational efficiency, maximize local content, and drive continued safety improvements.
'This contract extension is a testament to the strong working relationship between KBR and BOC, and further reinforces KBR's ongoing commitment to Iraq's national energy strategy and the sustainable development of the Majnoon field, one of the most strategic assets in the country,' said Jay Ibrahim, President, KBR Sustainable Technology Solutions. 'KBR is committed to support local development and contribute to Iraq's long-term domestic capacity enhancement.'
'KBR will continue to be our strategic partner in EPCM projects in Majnoon, successfully supporting our long-term development goals and maximizing field potential through safe, efficient, and sustainable project execution,' said Mr. Kadhim Kareem, CEO of the Majnoon Field at Basra Oil Company.
KBR's team in Iraq comprises a high number of local professionals to meet the targeted percentages at the Majnoon site and other regional hubs, ensuring the seamless execution of ongoing and upcoming projects as part of the Growth II Program.
About KBRWe deliver science, technology and engineering solutions to governments and companies around the world. KBR employs approximately 38,000 people worldwide with customers in more than 80 countries and operations in over 29 countries. KBR is proud to work with its customers across the globe to provide technology, value-added services, and long-term operations and maintenance services to ensure consistent delivery with predictable results. At KBR, We Deliver.
Visit www.kbr.com
Forward Looking Statements
The statements in this press release that are not historical statements, including statements regarding project performance and outcomes and future demand for the company's services, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks, uncertainties and assumptions, many of which are beyond the company's control, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks, uncertainties and assumptions include, but are not limited to, those set forth in the company's most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks and other U.S. Securities and Exchange Commission filings, which discuss some of the important risks, uncertainties and assumptions that the company has identified that may affect its business, results of operations and financial condition. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
For further information, please contact:
Jamie DuBrayVice President, Investor Relations713-753-5082Investors@kbr.com
Philip IvyVice President, Global Communications and Marketing 713-753-3800MediaRelations@kbr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
Earnings Teleconference Moves to Earlier Time on July 29
--(BUSINESS WIRE)--As previously announced, UnitedHealth Group will release its second quarter 2025 financial results on Tuesday, July 29, 2025, before the market opens. The start time for the teleconference has moved to 8:00 a.m. ET, 45 minutes earlier than previously announced, to allow more time for discussion of results with analysts and investors. This call will be webcast on the Investor Relations page of the company's website ( The replay will be available through August 12 on the website. UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn.
Business Wire
25 minutes ago
- Business Wire
SYNOVUS FINANCIAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Synovus Financial Corp.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of Synovus Financial Corp. (NYSE: SNV) and Pinnacle Financial Partners (NasdaqGS: PNFP). Upon completion of the proposed transaction, Synovus shareholders will own approximately 48.5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Synovus shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Yahoo
41 minutes ago
- Yahoo
Why Elanco (ELAN) Stock Is Trading Up Today
What Happened? Shares of animal health company Elanco (NYSE:ELAN) jumped 3% in the pre-market session after the company received approval from the European Commission for its canine dermatitis treatment, Zenrelia. The treatment, Zenrelia, was approved as a once-daily oral medication to treat itching and atopic dermatitis in dogs. This decision by the European Commission represented a significant milestone for Elanco, allowing it to expand its presence in the European canine dermatology market. The company stated the product was expected to be available by the end of the third quarter of 2025. The news followed a recent analyst upgrade from UBS Group, which raised its price target on Elanco shares to $18.00 from $17.00, reiterating a 'buy' rating on the stock. After the initial pop the shares cooled down to $14.85, up 1.1% from previous close. Is now the time to buy Elanco? Access our full analysis report here, it's free. What Is The Market Telling Us Elanco's shares are quite volatile and have had 16 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 3 months ago when the stock gained 21.2% on the news that the company reported decent first quarter 2025 results which beat analysts' EPS expectations and included constant currency revenue outperformance. Organic sales were up 4%, thanks to strong demand in cattle health and good traction from new pet meds like Credelio Quattro. Even though sales were flat, operating margins improved, a sign they're managing prices and costs pretty well. On the other hand, its full-year EBITDA guidance missed. Overall, we think this was a decent quarter with some key metrics above expectations. Elanco is up 23.2% since the beginning of the year, and at $14.85 per share, it is trading close to its 52-week high of $15.47 from August 2024. Investors who bought $1,000 worth of Elanco's shares 5 years ago would now be looking at an investment worth $696.95. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
